{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T08:27:06Z","timestamp":1784708826879,"version":"3.55.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.vaccine.2024.06.046","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T11:46:40Z","timestamp":1718970400000},"page":"126079","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Applicability of selected Brighton Collaboration case definitions in low-resource settings: A prospective hospital-based active surveillance in Addis Ababa, Ethiopia"],"prefix":"10.1016","volume":"42","author":[{"given":"Kassech","family":"Sintayehu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Shaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelalem Tazu","family":"Bonger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eden","family":"Dagnachew Zeleke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biniyam Tedla","family":"Mamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abenezer Abraham","family":"Anito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawit","family":"Bekele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley T.","family":"Longley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habtamu","family":"Gashaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asnakech","family":"Alemu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desalegne","family":"Degefaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4344-9567","authenticated-orcid":false,"given":"Wan-Ting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2024.06.046_b0005","doi-asserted-by":"crossref","first-page":"26","DOI":"10.46234\/ccdcw2019.009","article-title":"The importance of active surveillance in the assessment of vaccine safety","volume":"1","author":"Black","year":"2019","journal-title":"China CDC Wkly"},{"key":"10.1016\/j.vaccine.2024.06.046_b0010","unstructured":"The Uppsala Monitoring Centre. WHO collaborating centre for international drug monitoring: adverse reaction terminology (WHO-ART)."},{"key":"10.1016\/j.vaccine.2024.06.046_b0015","unstructured":"International Conference on Harmonization. The medical dictionary for regulatory activities."},{"key":"10.1016\/j.vaccine.2024.06.046_b0020","unstructured":"Sentinel Surveillance of Adverse Events of Special Interest (AESIs) After Vaccination with Covid-19 Vaccines Protocol Template o be used as a template for observational study protocols addendum to covid-19 vaccines: safety surveillance manual-module on monitoring and responding to adverse events of special interest (AESI)."},{"key":"10.1016\/j.vaccine.2024.06.046_b0025","unstructured":"Kohl KS, Bonhoeffer J, Miles Braun M, Chen RT, Duclos P, Heijbel H, et al. The Brighton Collaboration: Creating a Global Standard for Case Definitions (and Guidelines) for Adverse Events Following Immunization [Internet]. Available from: http:\/\/www.cochrane.org\/."},{"key":"10.1016\/j.vaccine.2024.06.046_b0030","unstructured":"CIOMS Cumulative Pharmacovigilance Glossary GS. Council for International Organizations of Medical Sciences; 2023."},{"key":"10.1016\/j.vaccine.2024.06.046_b0035","unstructured":"Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on reports of Guillain-Barr\u00e9 Syndrome (GBS) following adenovirus vector COVID-19 vaccines: https:\/\/www.who.int\/news\/item\/26-07-2021-statement-of-the-who-gacvs-covid-19-subcommittee-on-gbs."},{"key":"10.1016\/j.vaccine.2024.06.046_b0040","unstructured":"Tikur Anbessa Specialized Hospital [Internet]. [cited 2023 Oct 16]. Available from: http:\/\/www.aau.edu.et\/chs\/tikur-anbessa-specialized-hospital\/background-of-tikur-anbessa-hospital\/."},{"key":"10.1016\/j.vaccine.2024.06.046_b0045","unstructured":"Barbara Law. Safety Platform for Emergency Vaccines."},{"key":"10.1016\/j.vaccine.2024.06.046_b0050","unstructured":"Brighton Collaboration. CASE DEFINITION COMPANION GUIDES: https:\/\/speacsafety.net\/tools\/companion-guides\/."},{"key":"10.1016\/j.vaccine.2024.06.046_b0055","unstructured":"Brighton Collaboration. Case Definitions: https:\/\/brightoncollaboration.org\/case-definitions-table-view\/."},{"key":"10.1016\/j.vaccine.2024.06.046_b0060","unstructured":"The Task force for Global Health. CASE DEFINITION COMPANION GUIDES: https:\/\/speacsafety.net\/tools\/companion-guides\/."},{"key":"10.1016\/j.vaccine.2024.06.046_b0065","unstructured":"Open Data Kit; https:\/\/opendatakit.org\/%22."},{"key":"10.1016\/j.vaccine.2024.06.046_b0070","unstructured":"Causality assessment of an adverse event following immunization (AEFI) User manual for the revised WHO classification."},{"issue":"3","key":"10.1016\/j.vaccine.2024.06.046_b0075","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain-Barr\u00e9 syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2024.06.046_b0080","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1016\/j.vaccine.2011.01.007","article-title":"Guillain-Barr\u00e9 syndrome following receipt of influenza A (H1N1) 2009 monovalent vaccine in Korea with an emphasis on Brighton Collaboration case definition","volume":"29","author":"Choe","year":"2011","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2024.06.046_b0085","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/jns.12411","article-title":"The Brighton Collaboration case definition: comparison in a retrospective and prospective cohort of children with Guillain-Barr\u00e9 syndrome","volume":"25","author":"Korinthenberg","year":"2020","journal-title":"J Peripher Nerv Syst"},{"issue":"3","key":"10.1016\/j.vaccine.2024.06.046_b0090","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/jns.12398","article-title":"Diagnosis of Guillain-Barr\u00e9 syndrome and validation of the Brighton criteria in Malaysia","volume":"25","author":"Tan","year":"2020","journal-title":"J Peripher Nerv Syst"},{"issue":"4","key":"10.1016\/j.vaccine.2024.06.046_b0095","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/jns.12189","article-title":"Guillain-Barr\u00e9 syndrome in Bangladesh: validation of Brighton criteria","volume":"21","author":"Islam","year":"2016","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"10.1016\/j.vaccine.2024.06.046_b0100","first-page":"21","article-title":"Guillain-Barr\u00e9 syndrome in Ethiopian patients","volume":"43","author":"Melaku","year":"2005","journal-title":"Ethiop Med J"},{"key":"10.1016\/j.vaccine.2024.06.046_b0105","unstructured":"COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS): updated guidance regarding myocarditis and pericarditis reported with COVID-19 mRNA vaccines; https:\/\/www.who.int\/news\/item\/09-07-2021-gacvs-guidance-myocarditis-pericarditis-covid-19-mrna-vaccines."},{"issue":"10","key":"10.1016\/j.vaccine.2024.06.046_b0110","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.vaccine.2021.11.074","article-title":"Myocarditis and pericarditis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"40","author":"Kristen Sexson Tejtel","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.06.046_b0115","doi-asserted-by":"crossref","DOI":"10.33321\/cdi.2023.47.2","article-title":"A comparison of post-COVID vaccine myocarditis classification using the Brighton Collaboration criteria versus Centre for Disease Control criteria","volume":"47","author":"Marshall","year":"2023","journal-title":"Commun Dis Intell (2018)"},{"issue":"15","key":"10.1016\/j.vaccine.2024.06.046_b0120","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1016\/j.vaccine.2022.11.027","article-title":"Anaphylaxis: revision of the Brighton collaboration case definition","volume":"41","author":"Gold","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.06.046_b0125","unstructured":"VSQ-spring-2023.docx."},{"key":"10.1016\/j.vaccine.2024.06.046_b0130","unstructured":"Huang W-T, Owen Yang T, Law B, Black S, Sturkenboom M, Chen R. Use and performance of Brighton Collaboration case definitions in low-middle income settings. In: Abstracts of the 37th international conference on pharmacoepidemiology & therapeutic risk management. Pharmacoepidemiol Drug Saf 2021;30(1):381."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24007205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24007205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T18:05:23Z","timestamp":1729015523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24007205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":26,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0264410X24007205"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.06.046","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Applicability of selected Brighton Collaboration case definitions in low-resource settings: A prospective hospital-based active surveillance in Addis Ababa, Ethiopia","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.06.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126079"}}